Editas Medicine, a Cambridge, MA-based developer of genome-editing technology, raised $20m in venture capital funding.
Backers included Deerfield Management Company, L.P.‘s Deerfield Healthcare Innovations Fund, L.P., and Deerfield Private Design Fund III.
The company intends to use the funds for the advancement of multiple new therapies into studies which can prove their utility.
Led by Katrine Bosley, CEO, Editas Medicine is a genome editing company which aims to bring specific expertise in CRISPR/Cas9 and TALENs technologies and translate them into novel solutions to treat a broad range of genetically driven diseases.
FinSMEs
10/08/2015